||A population-based case-control study on the associations of Angelica sinensis with breast cancer
||Graduate Institute of Public Health(on the job class)
Health insurance database
A population-based case-control study on the association of herbal Angelica sinensis exposure with risk of breast cancer
Department of Public Health & College of Medicine National Cheng Kung University
This case-control study, including 34,262 women with breast cancer diagnosis and 102,786 matched controls identified from medical claims of 1-million Taiwan’s National Health Insurance program beneficiaries in 2005-2008, was conducted to investigate the relationships between Angelica sinensis and breast cancer. After controlling potential confounding factors, we found that the use of single and compound prescription of Angelica sinensis and breast cancer risk showed a weak but significant protective effect. Further analysis of the dose-response relationship also showed that the protective effect was positively correlated with the increase in the dose of the single and compound prescription of Angelica sinensis, and the trend test also revealed statistically significant. In addition, the analysis of the induction period of Angelica still showed that the protective effect was positively correlated with the increase of the induction period of Angelica sinensis. Besides, we found that the protective effect of Angelica reached related peak under the first Angelica exposure during the 47-55 years old. In the end, we also attempted to analyze other herbs which was known contained phytohormone include Pueraria and Dioscorea polystachya. And the adjusted odds ratio of breast cancer was similar to the exposure of Angelica sinensis revealed statistically weak protective effect or no statistical difference.
Since hormone replacement therapy had been found to increase the risk of breast cancer, the scientists also had concerns about the breast cancer carcinogenic effect of phytohormone contained in herbs of traditional Chinese medicines, especially Angelica, which is commonly used to improve gynecological menopausal symptoms. In the related research of Angelica, some researchers found that Angelica extract could stimulate the proliferation of breast cancer cells. However, the results observed in the subsequent experiments were not consistent. It was even observed that some Angelica extract had anti-cancer effects such as inhibiting estrogen activity or promoting apoptosis of breast cancer cells. By far, there is no consensus on the issue of angelica and breast cancer risk relationship. Therefore, the study was conducted to investigate the association of Angelica sinensis with breast cancer risk in women by retrospective use of Taiwan's health insurance database. It was expected that the results of this study can provide better epidemiological evidence for the long-term debate over the putative link between angelica and breast cancer risk.
MATERIAL AND METHODS
We conducted a case-control study design based on Taiwan’s National Health Insurance claim data (medical claims of all cancer patients and of a random sample of 1-million people registgered in 2005) released by the National Health Research Institutes. The case series was all newly diagnosed breast cancer patient with catastrophic illness registration in Taiwan between 2005-2008; the control group was randomly selected from the 1-million beneficiaries who registered with the National Health Insurance program in 2005 who had no breast cancer diagnosis between 2000 and 2008. We employed the time density sampling method to select controls who were matched to case on date of breast cancer diagnosis and age, with a case/control ratio of 1/3. Exposure of angelica and other potential confounders was retrospectively retrieved between 2000/1/1 and date of breast cancer diagnosis. Logistic regression models were used in the analysis with SAS 9.4.
After controlling for potential confounders, we found that the use of single and compound prescription of Angelica sinensis and breast cancer risk showed a weak but significant protective effect, the covariate adjusted odds ratio of breast cancer incidence was 0.93 (95% confidence interval 0.90-0.96; P value <0.0001). Further analysis of the dose-response relationship also showed that the protective effect was positively correlated with the dose of single and compound prescription of Angelica sinensis; and the trend test was statistically significant. In addition, the analysis of the induction period of Angelica showed that the protective effect was positively correlated with the duration of exposure to Angelica sinensis. And we found that the protective effect of Angelica sinensis became statistically significant after five years of exposure. Besides, we found that the protective effect of Angelica reached related peak for the first Angelica exposure at 47-55 years of age, with an adjusted odds ratio of 0.89 (95% confidence interval 0.85-0.93; P value <0.0001). We also attempted to analyze other herbs which was known to contain phytohormone including Pueraria and Dioscorea polystachya. Similar to the effect of Angelica sinensis, the aOR of breast cancer associated with Pueraria and Dioscorea also suggested null or weak but significantly protective effect.
This population-based case-control study suggested that exposure to Angelica sinensis showed a weak but significant protective effect on breast cancer risk. The results remained intact after various falsification approaches and sensitivity analyses.
第1章 前言 1
1.1 研究目的 2
第2章 文獻回顧 3
2.1 當歸之簡介 3
2.2 當歸與乳癌之相關研究 3
2.3 當歸相關研究小結 5
2.4 乳癌之簡介 6
2.5 乳癌之危險因子 6
2.5.1 乳癌病史 6
2.5.2 乳癌家族史 6
2.5.3 年齡 7
126.96.36.199 初經與更年期年齡 7
2.5.4 肥胖 8
2.5.6 內源性荷爾蒙 9
188.8.131.52 雌激素 9
2.5.7 其他危險因子 9
184.108.40.206 骨質密度 9
220.127.116.11 身高 10
18.104.22.168 良性乳腺疾病 10
2.5.8 台灣健保資料庫乳癌風險研究 10
2.6 乳癌文獻小結 11
第3章 材料與方法 12
3.1 研究問題 12
3.3 研究設計 14
3.3.1 研究對象定義與選取 15
3.3.2 當歸暴露的操作型定義 16
3.3.3 各類危險因子操作型定義 16
3.3.4 人口基本資料定義與擷取 17
3.4 資料分析 17
3.4.1 描述性統計 17
3.4.2 分析性統計 17
3.4.3 敏感度分析 18
第4章 結果 20
4.1 基本資料 20
4.2 當歸暴露與乳癌發生之勝算比 21
4.3 當歸暴露與乳癌發生之劑量反應關係 22
4.4 當歸暴露期時間長短與乳癌風險 23
4.5 否證分析 – 針灸暴露與乳癌風險 24
4.6 更年期與當歸對乳癌發病風險之影響 25
4.7 敏感度分析 – 黃體酮 25
4.8 敏感度分析 – 乳房良性腫瘤 26
4.9 含植物性荷爾蒙中藥與乳癌風險觀察 27
第5章 討論 29
5.1 當歸的乳癌風險分析結果 29
5.2 過去文獻比較與相關機轉討論 29
5.3 研究優勢與限制 31
5.3.1 研究優勢 31
5.3.1 研究限制 31
第6章 結論 33
1. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet, 1997. 350(9084): p. 1047-59.
2. Rossouw, J.E., et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002. 288(3): p. 321-33.
3. Amato, P., S. Christophe, and P.L. Mellon, Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause, 2002. 9(2): p. 145-50.
4. Lau, C.B., et al., Use of dong quai (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer: is it appropriate? Menopause, 2005. 12(6): p. 734-40.
5. Zhang, C.Z., et al., In vitro estrogenic activities of Chinese medicinal plants traditionally used for the management of menopausal symptoms. J Ethnopharmacol, 2005. 98(3): p. 295-300.
6. Godecke, T., et al., Integrated standardization concept for Angelica botanicals using quantitative NMR. Fitoterapia, 2012. 83(1): p. 18-32.
7. Zhou, W.J., et al., Angelica sinensis polysaccharides promotes apoptosis in human breast cancer cells via CREB-regulated caspase-3 activation. Biochem Biophys Res Commun, 2015. 467(3): p. 562-9.
8. Du, J., et al., Ligustilide inhibits spontaneous and agonists- or K+ depolarization-induced contraction of rat uterus. J Ethnopharmacol, 2006. 108(1): p. 54-8.
9. Su, Y.W., et al., Ligustilide prevents LPS-induced iNOS expression in RAW 264.7 macrophages by preventing ROS production and down-regulating the MAPK, NF-kappaB and AP-1 signaling pathways. Int Immunopharmacol, 2011. 11(9): p. 1166-72.
10. Piersen, C.E., Phytoestrogens in botanical dietary supplements: implications for cancer. Integr Cancer Ther, 2003. 2(2): p. 120-38.
11. Hajirahimkhan, A., B.M. Dietz, and J.L. Bolton, Botanical modulation of menopausal symptoms: mechanisms of action? Planta Med, 2013. 79(7): p. 538-53.
12. Liu, J., et al., Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem, 2001. 49(5): p. 2472-9.
13. Circosta, C., et al., Estrogenic activity of standardized extract of Angelica sinensis. Phytother Res, 2006. 20(8): p. 665-9.
14. Qi, H., et al., Sensitization of tamoxifen-resistant breast cancer cells by Z-ligustilide through inhibiting autophagy and accumulating DNA damages. Oncotarget, 2017. 8(17): p. 29300-29317.
15. Ma, H., et al., Z-ligustilide restores tamoxifen sensitivity of ERa negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERa. Oncotarget, 2017. 8(17): p. 29328-29345.
16. Hsieh, S.C., et al., The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database. Pharmacoepidemiol Drug Saf, 2008. 17(6): p. 609-19.
17. Lin, Y.H. and J.H. Chiu, Use of Chinese medicine by women with breast cancer: a nationwide cross-sectional study in Taiwan. Complement Ther Med, 2011. 19(3): p. 137-43.
18. Lai, J.N., C.T. Wu, and J.D. Wang, Prescription pattern of chinese herbal products for breast cancer in taiwan: a population-based study. Evid Based Complement Alternat Med, 2012. 2012: p. 891893.
19. Torre, L.A., et al., Global cancer statistics, 2012. CA Cancer J Clin, 2015. 65(2): p. 87-108.
20. DeSantis, C., et al., Breast cancer statistics, 2013. CA Cancer J Clin, 2014. 64(1): p. 52-62.
21. Liu, L., et al., Invasive breast cancer incidence trends by detailed race/ethnicity and age. Int J Cancer, 2012. 130(2): p. 395-404.
22. Gomez, S.L., et al., Hidden breast cancer disparities in Asian women: disaggregating incidence rates by ethnicity and migrant status. Am J Public Health, 2010. 100 Suppl 1: p. S125-31.
23. Wu, A.H., et al., Body size, hormone therapy and risk of breast cancer in Asian-American women. Int J Cancer, 2007. 120(4): p. 844-52.
24. Shin, H.R., et al., Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control, 2010. 21(11): p. 1777-85.
25. Shen, Y.C., et al., Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev, 2005. 14(8): p. 1986-90.
26. Nichols, H.B., et al., Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol, 2011. 29(12): p. 1564-9.
27. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet, 2001. 358(9291): p. 1389-99.
28. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer Statistics, 2017. CA Cancer J Clin, 2017. 67(1): p. 7-30.
29. Kelsey, J.L., M.D. Gammon, and E.M. John, Reproductive factors and breast cancer. Epidemiol Rev, 1993. 15(1): p. 36-47.
30. Colditz, G.A. and B. Rosner, Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol, 2000. 152(10): p. 950-64.
31. Rosner, B., G.A. Colditz, and W.C. Willett, Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol, 1994. 139(8): p. 819-35.
32. Bruzzi, P., et al., Short term increase in risk of breast cancer after full term pregnancy. Bmj, 1988. 297(6656): p. 1096-8.
33. Lauby-Secretan, B., et al., Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med, 2016. 375(8): p. 794-8.
34. Eliassen, A.H., et al., Adult weight change and risk of postmenopausal breast cancer. Jama, 2006. 296(2): p. 193-201.
35. van den Brandt, P.A., et al., Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol, 2000. 152(6): p. 514-27.
36. Nelson, H.D., et al., Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med, 2012. 156(9): p. 635-48.
37. Beral, V. and C. Million Women Study, Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 2003. 362(9382): p. 419-27.
38. Nyante, S.J., et al., Risk factors for specific histopathological types of postmenopausal breast cancer in the NIH-AARP Diet and Health Study. Am J Epidemiol, 2013. 178(3): p. 359-71.
39. Clemons, M. and P. Goss, Estrogen and the risk of breast cancer. N Engl J Med, 2001. 344(4): p. 276-85.
40. Beattie, M.S., et al., Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). J Natl Cancer Inst, 2006. 98(2): p. 110-5.
41. Farhat, G.N., et al., Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst, 2011. 103(7): p. 562-70.
42. Key, T., et al., Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst, 2002. 94(8): p. 606-16.
43. Lippman, M.E., et al., Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol, 2001. 19(12): p. 3111-6.
44. Missmer, S.A., et al., Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst, 2004. 96(24): p. 1856-65.
45. Sieri, S., et al., Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev, 2009. 18(1): p. 169-76.
46. Eliassen, A.H., et al., Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst, 2006. 98(19): p. 1406-15.
47. Dorgan, J.F., et al., Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Res, 2010. 12(6): p. R98.
48. Wysowski, D.K., et al., Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol, 1987. 125(5): p. 791-9.
49. Thomas, H.V., et al., A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer, 1997. 75(7): p. 1075-9.
50. Chen, Z., et al., Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer, 2008. 113(5): p. 907-15.
51. Qu, X., et al., Bone mineral density and risk of breast cancer in postmenopausal women. Breast Cancer Res Treat, 2013. 138(1): p. 261-71.
52. Ahlgren, M., et al., Growth patterns and the risk of breast cancer in women. N Engl J Med, 2004. 351(16): p. 1619-26.
53. Lahmann, P.H., et al., Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer, 2004. 111(5): p. 762-71.
54. Green, J., et al., Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol, 2011. 12(8): p. 785-94.
55. Ritte, R., et al., Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study. Int J Cancer, 2013. 132(11): p. 2619-29.
56. Dupont, W.D. and D.L. Page, Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med, 1985. 312(3): p. 146-51.
57. London, S.J., et al., A prospective study of benign breast disease and the risk of breast cancer. Jama, 1992. 267(7): p. 941-4.
58. Hartmann, L.C., et al., Benign breast disease and the risk of breast cancer. N Engl J Med, 2005. 353(3): p. 229-37.
59. Gram, I.T., et al., Smoking and Risk of Breast Cancer in a Racially/Ethnically Diverse Population of Mainly Women Who Do Not Drink Alcohol: The MEC Study. Am J Epidemiol, 2015. 182(11): p. 917-25.
60. Hansen, J. and R.G. Stevens, Case-control study of shift-work and breast cancer risk in Danish nurses: impact of shift systems. Eur J Cancer, 2012. 48(11): p. 1722-9.
61. Guibout, C., et al., Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol, 2005. 23(1): p. 197-204.
62. Chuang, S.C., et al., Associations between Medical Conditions and Breast Cancer Risk in Asians: A Nationwide Population-Based Study in Taiwan. PLoS One, 2015. 10(11): p. e0143410.
63. Alberts, J.F., et al., Socioeconomic inequity in health care: a study of services utilization in Curacao. Soc Sci Med, 1997. 45(2): p. 213-20.
64. Wu, A.H., et al., Epidemiology of soy exposures and breast cancer risk. Br J Cancer, 2008. 98(1): p. 9-14.
65. Gilani, G.S., Phytoestrogens and health. 2002: Champaign, Ill. : AOCS Press,.
66. Tsai, N.M., et al., The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem, 2006. 99(4): p. 1251-62.
67. Chen, Y.L., et al., The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide as pharmaceuticals on hepatocellular carcinoma cell therapy. Mol Pharmacol, 2008. 74(4): p. 1046-58.
68. Kan, W.L., et al., Study of the anti-proliferative effects and synergy of phthalides from Angelica sinensis on colon cancer cells. J Ethnopharmacol, 2008. 120(1): p. 36-43.
69. Cao, W., et al., [Structural analysis and anti-tumor activity in vivo of polysaccharide APS-2a from Angelica sinensis]. Zhong Yao Cai, 2008. 31(2): p. 261-6.